MétaCan
Menu
Back to cohort
Record W4406771622 · doi:10.1016/j.clml.2025.01.010

Minimal Residual Disease Testing Infrastructure in Multiple Myeloma: Guidance for Clinical Trial and Routine Practice Use in Canada

2025· review· en· W4406771622 on OpenAlexafffundabout
Hira Mian, Alissa Visram, Steven Chun-Min Shih, Suzanne Trudel, Annette E. Hay, Richard Leblanc, Michaël Sébag, Rayan Kaedbey, Julie Stakiw, Irwindeep Sandhu, Chai W. Phua, Philip Kuruvilla, Ibraheem Othman, Graeme Quest, David P. McMullen, Gabriele Colasurdo, Rami Kotb, Christopher P. Venner

Bibliographic record

VenueClinical Lymphoma Myeloma & Leukemia · 2025
Typereview
Languageen
FieldMedicine
TopicMultiple Myeloma Research and Treatments
Canadian institutionsUniversity of British ColumbiaUniversity of ManitobaWilliam Osler Health SystemSaskatchewan Science CentreLondon Health Sciences CentreUniversity of AlbertaUniversity of SaskatchewanUniversity of OttawaKingston Health Sciences CentreMcGill UniversityMcGill University Health CentreHôpital Maisonneuve-RosemontCancerCare ManitobaSaskatchewan Cancer AgencyOttawa HospitalPrincess Margaret Cancer CentreJewish General HospitalWestern UniversityUniversity of TorontoQueen's UniversityMcMaster University
FundersJanssen Research and DevelopmentJohnson and JohnsonHamilton Health Sciences
KeywordsMedicineMultiple myelomaMinimal residual diseaseResidualClinical trialClinical PracticeDiseaseOncologyInternal medicineIntensive care medicineFamily medicineBone marrowAlgorithm

Abstract

fetched live from OpenAlex

Measurable/minimal residual disease (MRD) is 1 of the most powerful prognostic factors for progression-free survival and overall survival in multiple myeloma (MM) and may guide therapeutic approaches. Here, we provide an overview of the current state of MRD testing in MM in Canada, highlighting its current use, approaches, and barriers. Furthermore, we discuss the available MRD assays and address questions on their appropriateness for routine practice and clinical trials. We also provide insights into timepoints for MRD testing and the relevance of achieving durable MRD negativity. The consensus recommendations herein were agreed upon by Canadian hematologists practicing at academic cancer centers and community cancer centers, clinical trial investigators, laboratory personnel, MM patients, and took into consideration the Canadian therapeutic landscape and the impact of anticipated regulatory approvals.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.022
metaresearch head score (Gemma)0.039
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.963
Threshold uncertainty score0.632

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0220.039
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0020.002
Bibliometrics0.0050.008
Science and technology studies0.0020.002
Scholarly communication0.0050.002
Open science0.0050.002
Research integrity0.0040.004
Insufficient payload (model declined to judge)0.0080.003

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.172
GPT teacher head0.446
Teacher spread0.274 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations3
Published2025
Admission routes3
Has abstractyes

Explore more

Same venueClinical Lymphoma Myeloma & LeukemiaSame topicMultiple Myeloma Research and TreatmentsFrench-language works237,207